RS7435335 located in the UGT2B7 gene may be a possible genetic marker for the clinical response and prognosis of breast cancer patients receiving neoadjuvant chemotherapy
Authors:
- 14 December 2018
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (5) , 7167-7173
Abstract
Objective: To evaluate the predictive efficacy and prognostic value of rs7435335 located in the UGT2B7 gene as a genetic marker in breast cancer patients receiving neoadjuvant chemotherapy (NAC).Methods: A total of 190 patients with breast cancer treated with NAC were enrolled to detect the rs7435335 SNP by sequenom. Miller‐Payne grades were used to evaluate the treatment efficacy. The association between rs7435335 and chemotherapy efficacy and prognosis was analyzed.Results: Altogether, 42 cases (22.1%) achieved pathologic complete response (pCR). The results of the univariate analysis showed that rs7435335 had no statistically significant difference with pCR and Miller‐Payne grades (P > 0.05). When grouping was done in accordance with the ER status, the pCR and Miller‐Payne grades significantly associated with rs7435335 ( P < 0.05) only in the ER‐negative group. Multivariate logistic regression analysis suggested that rs7435335 in the ER‐negative group was an independent predictor of pCR ( P < 0.05). Survival analysis showed that the disease‐free survival (DFS) time in patients with GA genotype was longer than that of GG genotype, and rs7435335 predicted the DFS in the ER‐negative group.Conclusion: The UGT2B7 rs7435335 is associated with the NAC efficacy and prognosis. Patients with GA genotype have better efficacy and prognosis. Rs7435335 was found to be a possible gene marker for pCR and prognosis in ER‐negative patients who received NAC.Keywords
This publication has 36 references indexed in Scilit:
- Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapyBMC Medicine, 2015
- Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation RatesAnnals of Surgery, 2015
- Drug-Metabolizing Activity, Protein and Gene Expression of UDP-Glucuronosyltransferases Are Significantly Altered in Hepatocellular Carcinoma PatientsPLOS ONE, 2015
- Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator?JNCI Monographs, 2015
- Impact of Neoadjuvant Chemotherapy on Locoregional Surgical Treatment of Breast CancerAnnals of Surgical Oncology, 2015
- Influence of Neoadjuvant Chemotherapy on Radiotherapy for Breast CancerAnnals of Surgical Oncology, 2015
- Current and future role of neoadjuvant therapy for breast cancerThe Breast, 2014
- Germline Genetic Variation, Cancer Outcome, and PharmacogeneticsJournal of Clinical Oncology, 2010
- Pharmacogenetics and human genetic polymorphismsBiochemical Journal, 2010
- Regulation Of Human Dihydropyrimidine Dehydrogenase: Implications in the Pharmacogenetics of 5-FU-based ChemotherapyPharmacogenomics, 2007